Abstract

The Thyroid Imaging and Reporting System (TIRADS) allows a sonographic assessment of the malignancy risk of thyroid nodules (TNs). To date, there is a lack of systematic data about the change in ultrasound (US) features after therapeutic interventions. The aim of this study was to characterize the changes in autonomously functioning thyroid nodules (AFTNs) after radioiodine therapy (RIT) by using TIRADS. We retrospectively assessed data from 68 patients with AFTNs treated with RIT between 2016 and 2018 who had available first and second follow-up US imaging. Before RIT, 69.1% of the AFTNs were classified as low-risk TNs when applying Kwak TIRADS (EU-TIRADS 52.9%), 22.1% were intermediate-risk TNs (EU-TIRADS 19.1%), and 8.8% were high-risk TNs (EU-TIRADS 27.9%). Twelve months after RIT, 22.1% of the AFTNs showed features of high-risk TNs according to Kwak TIRADS (EU-TIRADS 45.6%). The proportion of intermediate TNs also increased to 36.8% (EU-TIRADS 29.4%), and 41.2% were low-risk TNs (EU-TIRADS 25%). A significant percentage of AFTNs presented with features suspicious for malignancy according to TIRADS before RIT, and this number increased significantly after therapy. Therefore, before thyroid US, thorough anamnesis regarding prior radioiodine treatment is necessary to prevent unneeded diagnostic procedures.

Highlights

  • Functioning thyroid nodules (AFTNs) appear as hyperfunctioning on 99mTcO4− (99mTc-pertechnetate) scintigraphy with increased uptake of the tracer

  • The aim of this study was to characterize the changes in autonomously functioning thyroid nodules (AFTNs) after radioiodine therapy (RIT) by using Thyroid Imaging Reporting and Data System (TIRADS)

  • A significant percentage of AFTNs presented with features suspicious for malignancy according to TIRADS before RIT, and this number increased significantly after therapy

Read more

Summary

Introduction

Functioning thyroid nodules (AFTNs) appear as hyperfunctioning on 99mTcO4− (99mTc-pertechnetate) scintigraphy with increased uptake of the tracer. AFTNs present either as toxic or nontoxic depending on their effect on peripheral thyroid hormone levels. AFTNs are known to show suspicious US features in a substantial number of cases mimicking thyroid cancer [3,4]. Radioiodine therapy (RIT) represents a well-established and effective functional treatment for AFTNs. In Germany, RIT is performed after standardized radioiodine uptake measurements (“radioiodine testing”) to calculate the individual radioactivity dose for treatment. Post-treatment control via thyroid scan, analysis of peripheral thyroid hormone levels, and US imaging are applied three to six months after RIT to assess treatment success [7,8]. Detailed data are sparse about changes in US features of AFTNs after RIT

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call